(June 14, 2016, 1:15 PM EDT) -- ALEXANDRIA, Va. — A patented method of treating rheumatoid arthritis with anti-tumor necrosis factor α (anti-TNFα) combined with the anti-rheumatic drug methotrexate (MTX) is likely invalid, the Patent Trial and Appeal...
Patent Board Grants Inter Partes Review Of Arthritis Treatment Patent
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login